pioglitazone has been researched along with Squamous Cell Carcinoma of Head and Neck in 1 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Squamous Cell Carcinoma of Head and Neck: The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Handley, N | 1 |
| Eide, J | 1 |
| Taylor, R | 1 |
| Wuertz, B | 1 |
| Gaffney, P | 1 |
| Ondrey, F | 1 |
1 other study available for pioglitazone and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
PPARĪ³ targeted oral cancer treatment and additional utility of genomics analytic techniques.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Genomic | 2017 |